Phase II study of VELCADE in combination with Rituximab in patients with relapsed or progressed Non Hodgkin's Follicular Lymphoma.

Trial Profile

Phase II study of VELCADE in combination with Rituximab in patients with relapsed or progressed Non Hodgkin's Follicular Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Bortezomib (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01830465).
    • 31 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top